Literature DB >> 8526789

The role of plasma exchange in the treatment of severe forms of hemolytic-uremic syndrome in childhood.

J Slavicek1, Z Puretić, M Novak, V Sarnavka, V Benjak, S Glavas-Boras, S Thune.   

Abstract

Therapeutic plasma exchange (PE) or plasma-pheresis has been used in recent years in the treatment of severe hemolytic uremic syndrome (HUS) in children. We analyzed the benefit of PE and peritoneal dialysis (PD) in 9 children, 6 boys and 3 girls, aged 1-10 years, from 1983-1993. All children came from different geographical regions, and all had the sporadic form of the illness. Three patients had the gastrointestinal form, 5 had respiratory prodromes while 1 child developed HUS during the course of varicella. Seven children were hypertensive, but only in 3 was hypertension persistent. The child with varicella had a transient complement decrease. Five children were treated with PE. In 4 children, fresh frozen plasma (FFP) was used as replacement fluid, and human albumin was used in 1 child. Four children were treated with PD and infusions of FFP. Rapid recovery of renal function was observed in 5 patients whereas in 2 oliguric children the recovery of renal function ensued within 1 and 2 months, respectively. Two children developed terminal renal failure (TRF) (in 1 child the treatment was very delayed, and in other child HUS developed following varicella). Only 1 boy had relapses of the disease followed by impairment of renal function from which he gradually recovered. During the 3-10 year follow-up period, only the child with relapses was hypertensive while the others had normal clinical and laboratory parameters. We suggest that PE plays an important role in the early treatment of severe forms of HUS in children.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8526789     DOI: 10.1111/j.1525-1594.1995.tb02370.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  6 in total

Review 1.  Thrombotic microangiopathies: a general approach to diagnosis and management.

Authors:  Donald M Arnold; Christopher J Patriquin; Ishac Nazy
Journal:  CMAJ       Date:  2016-10-17       Impact factor: 8.262

2.  Clinical characteristics of children with hemolytic uremic syndrome in Hangzhou, China.

Authors:  Shui-Ai Zhao; Bo-Tao Ning; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2017-03-28       Impact factor: 2.764

Review 3.  Clinical practice. Today's understanding of the haemolytic uraemic syndrome.

Authors:  Johanna Scheiring; Alejandra Rosales; Lothar Bernd Zimmerhackl
Journal:  Eur J Pediatr       Date:  2009-08-26       Impact factor: 3.183

4.  A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.

Authors:  Paolo Giordano; Giuseppe Stefano Netti; Luisa Santangelo; Giuseppe Castellano; Vincenza Carbone; Diletta Domenica Torres; Marida Martino; Michela Sesta; Franca Di Cuonzo; Maria Chiara Resta; Alberto Gaeta; Leonardo Milella; Maria Chironna; Cinzia Germinario; Gaia Scavia; Loreto Gesualdo; Mario Giordano
Journal:  Pediatr Nephrol       Date:  2018-10-25       Impact factor: 3.714

5.  Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS).

Authors:  Paul N Goldwater; Karl A Bettelheim
Journal:  BMC Med       Date:  2012-02-02       Impact factor: 8.775

Review 6.  Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Johanna Scheiring; Sharon P Andreoli; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-08-13       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.